Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Zogenix Inc. ZGNX

Zogenix Inc is engaged in developing and commercializing therapeutic solutions for people living with serious and life-threatening rare CNS disorders and medical conditions. Its product candidate includes Fintepla, dose fenfluramine for the treatment of Dravet syndrome, and MT-1621 for a rare, life-threatening mitochondrial depletion disease, thymidine kinase 2 deficiency (TK2d). It operates as a single operating segment engaged in the research, development, and commercialization of pharmaceutical products.


NDAQ:ZGNX - Post by User

Bullboard Posts
Post by sneakysneakyon Jan 20, 2022 12:04am
137 Views
Post# 34336060

Big move, conviction like a lifer.

Big move, conviction like a lifer. CAN'T stop won't stop. Black Box Buzzing like a bee while you ZZzzzzzzzz!!!
Bullboard Posts